Serum resistin and adiponectin relationships with glucometabolic control in patients with type 2 diabetes mellitus

Abstract

Introduction/Objective Adiponectin and resistin are important adipokines that play an important role in the regulation of blood sugar, beta-oxidation in muscles, and insulin resistance. This study aimed to assess and compare the relationships of resistin and adiponectin concentrations with glucometabolic control in patients with type 2 diabetes mellitus (T2DM). Methods A total of 191 subjects were studied. The final selection included 107 patients with T2DM (67 males and 40 females) and 84 healthy control subjects (45 males and 39 females). Fasting venous blood samples were analyzed for glucose (FBG), glycosylated hemoglobin (HbA1c), insulin, lipids, adiponectin and resistin levels. Body composition was evaluated in all subjects by the body mass index (BMI) and waist-hip ratio (WHR). Results BMI, WHR, FBG, HbA1c, homeostatic model assessment of insulin resistance (HOMA-IR), total cholesterol, and triglycerides were significantly higher in individuals with T2DM compared to healthy volunteers. Serum resistin levels were significantly higher (p = 0.0259) and serum adiponectin levels were significantly lower (p = 0.0001) in T2DM patients than in control subjects. Adiponectin levels were significantly lower (p = 0.0411) in diabetes patients with poor glycemic control, compared to those with good glycemic control, while the difference was non-significant for resistin (p = 0.8899). Serum adiponectin levels were discordant with HbA1c (r =-0.274, p = 0.004). Linear-by-linear association showed significant trend of better glycemic control at increasing quartiles of adiponectin levels (p = 0.042), while the trend was not significant for resistin levels (p = 0.904). Multiple regression analysis revealed FBG, insulin, HOMA-IR, and HbA1c as significant predictors of adiponectin. Conclusions T2DM patients have significantly higher resistin and lower adiponectin levels compared to healthy controls. Adiponectin levels were significantly lower in patients with poor glycemic control.